Chemotherapy in the elderly: Are their needs being met?

Therapy

Volumn 6, Issue 6, 2009, Pages 893-902

  Lichtman, Stuart M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Ageism; Aging; Cancer; Chemotherapy; Clinical trials; Comorbidity; Elderly; Pharmacokinetics; Pharmacology; Polypharmacy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; PACLITAXEL;

AGING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMORBIDITY; CREATININE CLEARANCE; CYTOREDUCTIVE SURGERY; DAILY LIFE ACTIVITY; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ELDERLY CARE; FUNCTIONAL STATUS; HUMAN; NEOPLASM; OVARY CANCER; OVERALL SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE;

EID: 70449652875     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.72     Document Type: Review

References (116)

1. Lichtman SM: Drug development in the elderly. In: Handbook of anticancer drug development. Budman D, Calvert AH, Rowinsky EK (Eds). Lippincott Williams & Wilkins, PA, USA, 411-423 (2004).
2. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341, 2061-2067 (1999).
3. Yee KW, Pater JL, Pho L, Zee B, Siu LL: Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J. Clin. Oncol. 21, 1618-1623. (2003). (Pubitemid 46594117)
4. Talarico L, Chen G, Pazdur R: Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J. Clin. Oncol. 22, 4626-4631 (2004). (Pubitemid 41185131)
5. Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G: Older female cancer patients: importance, causes, and consequences of undertreatment. J. Clin. Oncol. 25, 1858-1869 (2007).
6. Shah RR: Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br. J. Clin. Pharmacol. 58, 452-469 (2004).
7. Kornblith AB, Kemeny M, Peterson BL et al.: Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 95, 989-996 (2002). (Pubitemid 34925347)
8. Kemeny MM, Peterson BL, Kornblith AB et al.: Barriers to clinical trial participation by older women with breast cancer. J. Clin. Oncol. 21, 2268-2275 (2003).
9. Black SA, Rush RD: Cognitive and functional decline in adults aged 75 and older. J. Am. Geriatr. Soc. 50, 1978-1986 (2002).
10. Hamerman D: Toward an understanding of frailty. Ann. Intern. Med. 130, 945-950 (1999).
11. Monfardini S, Gridelli C, Pasetto LM, Soubeyran P, Droz JP, Basso U: Vulnerable and frail elderly: an approach to the management of the main tumour types. Eur. J. Cancer 44, 488-493 (2008).
12. Fried LP, Tangen CM, Walston J et al.: Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56, M146-M156 (2001). (Pubitemid 32187141)
13. Balducci L, Stanta G: Cancer in the frail patient. A coming epidemic. Hematol. Oncol. Clin. North Am. 14, 235-250 (2000). (Pubitemid 30078440)
14. Balducci L, Extermann M: Management of the frail person with advanced cancer. Crit. Rev. Oncol. Hematol. 33, 143-148 (2000). (Pubitemid 30085478)
15. Balducci L: Supportive care in elderly cancer patients. Curr. Opin. Oncol. 21, 310-317 (2009).
16. Tumer N, Scarpace PJ, Lowenthal DT: Geriatric pharmacology: basic and clinical considerations. Annu. Rev. Pharmacol. Toxicol. 32, 271-302 (1992).
17. Shock NW, Watkin DM, Yiengst BS et al.: Age differences in water content of the body as related to basal oxygen consumption in males. J. Gerontol. 18, 1-8 (1963).
18. Forbes GB, Reina JC: Adult lean body mass declines with age: some longitudinal observations. Metabolism 19, 653-663 (1978).
19. Adelman LS, Liebman J: Anatomy of body water and electrolytes. Am. J. Med. 27, 256-277 (1959).
20. Yuen GJ: Altered pharmacokinetics in the elderly. Clin. Geriatr. Med. 6, 257-267 (1990).
21. Baker SD, Grochow LB: Pharmacology of cancer chemotherapy in the older person. Clin. Geriatr. Med. 13, 169-183 (1997).
22. Partridge AH: Non-adherence to endocrine therapy for breast cancer. Ann. Oncol. 17, 183-184 (2006).
23. Partridge AH, Avorn J, Wang PS, Winer EP: Adherence to therapy with oral antineoplastic agents. J. Natl Cancer Inst. 94, 652-661 (2002). (Pubitemid 34552485)
24. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J. Clin. Oncol. 26, 556-562 (2008). (Pubitemid 351264348)
25. Partridge AH, Wang PS, Winer EP, Avorn J: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J. Clin. Oncol. 21, 602-606 (2003).
26. Lichtman SM, Boparai MK: Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr. Treat. Options Oncol. 9, 191-203 (2008).
27. Egorin MJ: Cancer pharmacology in the elderly. Semin. Oncol. 20, 43-49 (1993).
28. Rossman I: Clinical geriatrics (2nd Edition). Lippincott, PA, USA, xxiii, 704 (1979).
29. Kotz CM, Billington CJ, Levine AS: Obesity and aging. Clin. Geriatr. Med. 15, 391-412 (1999).
30. Rosner GL, Hargis JB, Hollis DR et al.: Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J. Clin. Oncol. 14, 3000-3008 (1996).
31. 2: the experience from the program in Women's Oncology/ Brown Medical School. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 5570).
32. Ania BJ, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ 3rd: Incidence of anemia in older people: an epidemiologic study in a well defined population. J. Am. Geriatr. Soc. 45, 825-831 (1997).
33. Corti MC, Guralnik JM, Salive ME, Sorkin JD: Serum albumin level and physical disability as predictors of mortality in older persons. JAMA 272, 1036-1042 (1994).
34. Hazzard WR: Depressed albumin and high-density lipoprotein cholesterol: signposts along the final common pathway of frailty. J. Am. Geriatr. Soc. 49, 1253-1254 (2001).
35. Volpato S, Leveille SG, Corti MC, Harris TB, Guralnik JM: The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. J. Am. Geriatr. Soc. 49, 1142-1147 (2001). (Pubitemid 32900139)
36. Vestal RE: Aging and pharmacology. Cancer 80, 1302-1310 (1997).
37. Balducci L, Corcoran MB: Antineoplastic chemotherapy of the older cancer patient. Hematol. Oncol. Clin. North Am. 14, 193-212 (2000). (Pubitemid 30078438)
38. Brenner BM, Meyer GW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med. 307, 652-659 (1982).
39. Tauchi H, Tsuboi K, Okutoni J: Age changes in the human kidney of the different races. Gerontology 17, 87-97 (1971).
40. Evers BM, Townsend CMJ, Thompson JC: Organ physiology of aging. Surg. Clin. North Am. 74, 23-39 (1994).
41. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
42. Jelliffe RW: Estimation of creatinine clearance when urine cannot be collected. Lancet 1, 975-976 (1971).
43. Marx GM, Blake GM, Galani E et al.: Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann. Oncol. 15, 291-295 (2004). (Pubitemid 38262630)
44. Balducci L, Extermann M: Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 80, 1317-1322 (1997). (Pubitemid 27407235)
45. Skirvin JA, Lichtman SM: Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging 19, 25-42 (2002).
46. Kintzel PE, Dorr RT: Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat. Rev. 21, 33-64 (1995).
47. Launay-Vacher V, Oudard S, Janus N et al.: Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110, 1376-1384 (2007). (Pubitemid 47435612)
48. Thariat J, Azzopardi N, Peyrade F et al.: Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. J. Clin. Oncol. 26, 4223-4225 (2008).
49. Launay-Vacher V, Spano JP, Janus N et al.: Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup ana lysis of the IRMA study. Crit. Rev. Oncol. Hematol. 70, 124-133 (2009).
50. Launay-Vacher V, Karie S, Fau JB, Izzedine H, Deray G: Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J. Pain 6, 137-148 (2005). (Pubitemid 40365017)
51. Launay-Vacher V, Chatelut E, Lichtman S, Wildiers H, Steer C, Aapro M: Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann. Oncol. 18, 1314-1321 (2007). (Pubitemid 46070218)
52. Hurria A, Lichtman SM: Clinical pharmacology of cancer therapies in older adults. Br. J. Cancer 98, 517-522 (2008). (Pubitemid 351214530)
53. Lichtman SM, Wildiers H, Chatelut E et al.: International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients - an ana lysis of the medical literature. J. Clin. Oncol. 25, 1832-1843 (2007).
54. Wildiers H: Mastering chemotherapy dose reduction in elderly cancer patients. Eur. J. Cancer 43, 2235-2241 (2007).
55. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373-383 (1987). (Pubitemid 17055592)
56. Yancik R, Wesley MN, Ries LA et al.: Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 82, 2123-2134 (1998). (Pubitemid 28240818)
57. Satariano WA, Ragland DA: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann. Intern. Med. 120, 104-110 (1994).
58. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L: Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol. 16, 1582-1587 (1998). (Pubitemid 28175784)
59. Rockwood K, Stadnyk K, MacKnight C, McDowell I, Hebert R, Hogan DB: A brief clinical instrument to classify frailty in elderly people. Lancet 353, 205-206 (1999). (Pubitemid 29088034)
60. Reuben DB, Rubenstein LV, Hirsch SH, Hays RD: Value of functional status as a predictor of mortality: results of a prospective study. Am. J. Med. 93, 663-669 (1992).
61. Repetto L, Vercelli M, Simoni C et al.: Comorbidity among elderly patients with and without cancer. Proc. Am. Soc. Clin. Onc. 13, A1625 (1994).
62. Hurria A, Gupta S, Zauderer M et al.: Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104, 1998-2005 (2005).
63. Schubert CC, Gross C, Hurria A: Functional assessment of the older patient with cancer. Oncology (Williston Park) 22, 916-922; discussion 925, 928 (2008).
64. Venook A, Klein C, Kastrissios H et al.: Phase I study of Irinotecan (CPT-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 20, A293 (2001).
65. Venook AP, Egorin MJ, Rosner GL et al.: Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J. Clin. Oncol. 16, 1811-1819 (1998).
66. Venook AP, Egorin MJ, Rosner GL et al.: Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J. Clin. Oncol. 2780-2787 (2000).
67. Lichtman SM, Etcubanas E, Budman DR et al.: The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest. 20, 904-913 (2002). (Pubitemid 35315924)
68. Venook AP, Enders Klein C, Fleming G et al.: A Phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann. Oncol. 14, 1783-1790 (2003). (Pubitemid 38029051)
69. Miller AA, Murry DJ, Owzar K et al.: Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol. 27, 1800-1805 (2009).
70. Miller AA, Murry DJ, Owzar K et al.: Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J. Clin. Oncol. 25, 3055-3060 (2007). (Pubitemid 47218052)
71. Dash A, Galsky MD, Vickers AJ et al.: Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107, 506-513 (2006). (Pubitemid 44107210)
72. Vose JM, Armitage JO, Weisenburger DD et al.: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 6, 1838-1844 (1988).
73. Hughes KS, Schnaper LA, Berry D et al.: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N. Engl. J. Med. 351, 971-977 (2004). (Pubitemid 39166260)
74. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB: High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 267, 2191-2196 (1992).
75. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT: Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J. Natl Cancer Inst. 92, 613-621 (2000). (Pubitemid 30321303)
76. Cohen HJ, Feussner JR, Weinberger M et al.: A controlled trial of inpatient and outpatient geriatric evaluation and management. N. Engl. J. Med. 346, 905-912 (2002). (Pubitemid 34984640)
77. Extermann M, Aapro M, Bernabei R et al.: Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit. Rev. Oncol. Hematol. 55, 241-252 (2005). (Pubitemid 41219694)
78. Fries JF: Aging, natural death, and the compression of morbidity. N. Engl. J. Med. 303, 130-135 (1980).
79. Fries JF: Measuring and monitoring success in compressing morbidity. Ann. Intern. Med. 139, 455-459 (2003).
80. Burris HA, 3rd, Moore MJ, Andersen J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997).
81. Tannock IF, de Wit R, Berry WR et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004).
82. Tannock IF, Osoba D, Stockler MR et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14, 1756-1764 (1996). (Pubitemid 26185452)
83. High K, Bradley S, Loeb M, Palmer R, Quagliarello V, Yoshikawa T: A new paradigm for clinical investigation of infectious syndromes in older adults: assessing functional status as a risk factor and outcome measure. J. Am. Geriatr. Soc. 53, 528-535 (2005). (Pubitemid 41623537)
84. Cheung WY, Neville BA, Cameron DB, Cook EF, Earle CC: Comparisons of patient and physician expectations for cancer survivorship care. J. Clin. Oncol. 27, 2489-2495 (2009).
85. Earle CC: Cancer survivorship research and guidelines: maybe the cart should be beside the horse. J. Clin. Oncol. 25, 3800-3801 (2007).
86. Rowland JH, Hewitt M, Ganz PA: Cancer survivorship: a new challenge in delivering quality cancer care. J. Clin. Oncol. 24, 5101-5104 (2006). (Pubitemid 46623194)
87. Crawford J: Pegfilgrastim: the promise of pegylation fulfilled. Ann. Oncol. 14, 6-7 (2003).
88. Crawford J, Ozer H, Stoller R et al.: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Engl. J. Med. 325, 164-170 (1991).
89. Balducci L, Lyman GH: Patients aged > or =70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J. Clin. Oncol. 19, 1583-1585 (2001). (Pubitemid 32202566)
90. Borkowski JM, Duerr M, Donehower RC et al.: Relation between age and clearance rate of nine investigational anticancer drugs from Phase I pharmacokinetic data. Cancer Chemother. Pharmacol. 33, 493-496 (1994). (Pubitemid 24082344)
91. Grever MR, Grieshaber CK: Toxicology by organ system. In: Cancer medicine. Holland JF, Frei E (Eds). BC Decker, NY, USA (2000).
92. Lichtman SM, Boparai M: Geriatric medication management: evaluation of pharmacist interventions and potentially inappropriate medication (PIM) use in older (≥65 years) cancer patients. J. Clin. Oncol. 27(Suppl.), S15 (2009) (Abstract 9507).
93. Kivisto KT, Kroemer HK, Eichelbaum M: The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol. 40, 523-530 (1995).
94. King RS: Drug interactions with cancer chemotherapy. Cancer Pract. 3, 57-59 (1995).
95. Flockhart DA, Tanus-Santos JE: Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch. Intern. Med. 162, 405-412 (2002).
96. Ratain MJ, Staubus AE, Schilsky RL, Malspeis L: Limited sampling models for amonafide pharmacokinetics. Proc. Am. Assoc. Cancer Res. 29, 766A (1988).
97. Minami H, Beijnen JH, Verweij J, Ratain MJ: Limited sampling model for area under the concentration time curve of total topotecan. Clin. Cancer Res. 2, 43-46 (1996). (Pubitemid 26042177)
98. Mick R, Gupta E, Vokes EE, Ratain MJ: Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J. Clin. Oncol. 14, 2012-2019 (1996). (Pubitemid 26230101)
99. Ratain MJ, Robert J, van der Vijgh WJ: Limited sampling models for doxorubicin pharmacokinetics. J. Clin. Oncol. 9, 871-876 (1991).
100. Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA: A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res. 49, 3129-3133 (1989). (Pubitemid 19148657)
101. Ratain MJ, Staubus AE, Schilsky RL, Malspeis L: Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res. 48, 4127-4130 (1988).
102. Ratain MJ, Vogelzang NJ: Limited sampling model for vinblastine pharmacokinetics. Cancer Treat. Rep. 71, 935-939 (1987).
103. van Warmerdam LJ, ten Bokkel Huinink WW, Maes RA, Beijnen JH: Limited-sampling models for anticancer agents. J. Cancer Res. Clin. Oncol. 120, 427-433 (1994).
104. Tranchand B, Amsellem C, Chatelut E et al.: A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother. Pharmacol. 43, 316-322 (1999). (Pubitemid 29075889)
105. van Warmerdam LJ, Verweij J, Rosing H, Schellens JH, Maes RA, Beijnen JH: Limited sampling models for topotecan pharmacokinetics. Ann. Oncol. 5, 259-264 (1994). (Pubitemid 24097522)
106. Aarons L: Population pharmacokinetics: theory and practice. Br. J. Clin. Pharmacol. 32, 669-670 (1991).
107. Lichtman SM, Hollis D, Miller AA et al.: Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J. Clin. Oncol. 24, 1846-1851 (2006).
108. Muss HB, Berry DA, Cirrincione CT et al.: Adjuvant chemotherapy in older women with early-stage breast cancer. N. Engl. J. Med. 360, 2055-2065 (2009).
109. Schrag D, Cramer LD, Bach PB, Begg CB: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J. Natl Cancer Inst. 93, 850-857 (2001). (Pubitemid 32590779)
110. Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB: Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results - Medicare. J. Clin. Oncol. 19, 3712-3718 (2001). (Pubitemid 32844782)
111. Klepin H, Mohile S, Hurria A: Geriatric assessment in older patients with breast cancer. J. Natl Compr. Canc. Netw. 7, 226-236 (2009).
112. Hurria A, Mohile S, Lichtman S et al.: Geriatric assessment of older adults with cancer: baseline data from a 500 patient multicenter study. J. Clin. Oncol. 27(Suppl.), S15 (2009) (Abstract 9546).
113. Hurria A, Wong FL, Villaluna D et al.: Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. J. Clin. Oncol. 26, 5386-5392 (2008).
114. Audisio RA, Bozzetti F, Gennari R et al.: The surgical management of elderly cancer patients; recommendations of the SIOG surgical task force. Eur. J. Cancer 40, 926-938 (2004). (Pubitemid 38496248)
115. Repetto L, Comandini D, Mammoliti S: Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients. Crit. Rev. Oncol. Hematol. 37, 147-152 (2001). (Pubitemid 32109222)
116. Olivotto IA, Bajdik CD, Ravdin PM et al.: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J. Clin. Oncol. 23, 2716-2725 (2005).